<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031042</url>
  </required_header>
  <id_info>
    <org_study_id>2010/441-31/4</org_study_id>
    <nct_id>NCT02031042</nct_id>
  </id_info>
  <brief_title>Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
  <official_title>Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stockholm South General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stockholm South General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if sentinel lymph node biopsy is a reliable
      staging tool for breast cancer patients planned for neoadjuvant chemotherapy (=before breast
      surgery) and if, in that case, it is safe to omit axillary lymph node dissection if the
      sentinel lymph node is free of metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sentinel lymph node biopsy (SLNB) was introduced in the late 1990´s and has become standard
      procedure for staging of the axilla in early stage breast cancer associated with
      significantly less arm morbidity than axillary lymph node dissection (ALND).

      Neoadjuvant chemotherapy (NAC) given before breast surgery is indicated for locally advanced
      breast cancer but is increasingly used for early stage breast cancer with the purpose of
      downstaging the tumor and thereby possibly enabling breast conserving surgery. Traditionally,
      the standard axillary staging tool has been ALND although up to 50 per cent of the patients
      at diagnosis do not have any metastases in their axillary lymph nodes. In addition, NAC can
      eradicate metastases in the axillary lymph nodes in up to 40 per cent of the patients.

      SLNB has therefore been evaluated in the neoadjuvant setting both before and after NAC but is
      still controversial and the timing debated.

      This is a Swedish prospective multi-institutional study without any comparison goup. The
      comparison is between the findings in the SLNB and the following ALND performed after NAC in
      all patients.

      If the patient is clinically node-negative at diagnosis a SLNB is performed before (without
      frozen section) and after NAC (substudy I). The reasons for repeating SLNB both before and
      after NAC are 1) to find out what happens during NAC 2) if it is possible to identify a
      repeat SLNB and 3) if it is reliable.

      If the patient is node-positive at diagnosis (cytologically verified lymph node metastasis)
      SLNB is performed after NAC together with the breast operation and ALND (substudy II). When
      SLNB is performed after NAC, the sentinel lymph nodes are also analysed with frozen section
      in order to validate the method after chemotherapy. Both blue dye and radiolabelled isotope
      for localisation of the sentinel lymph node is recommended but lymphoscintigraphy is
      optional.

      All consecutive clinically node-negative (or with unclear nodal status after ultrasound and
      cytology) patients planned for NAC will have oral and written information about the study by
      the responsible surgeon. After accepting to participate, the patient is asked to sign a
      written consent. Patients with a cytologically verified lymph node metastasis/es at diagnosis
      will be informed and asked to participate in substudy II after completion of NAC.

      According to the statistical analysis, and with an expected loss of 10 per cent, a sample
      size of 220 patients is needed in substudy I to show that the false negative rate is less
      than 10 per cent. If we include 200 patients and 50 per cent are lymph node positive at
      diagnosis then the estimation of false negative rate will be based on 100 individuals. If we
      estimate the true false negative rate to be 8 per cent, then the precision with 80 per cent
      power will be +/- 7 per cent units (2-sided test with 95 per cent confidence interval).

      The Central Contact (PI) is responsible for data collection, management and analysis. Each
      protocol will be sent together with a written consent and copies of all relevant
      histopathological reports to the PI, who will control for missing or incongruent data and if
      so, ask the responsible investigator on that institution/hospital to complement the missing
      data from the patients journal (copies of medical records or histopathological reports).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The rate of patients with no metastasis/ses in their sentinel lymph node/s before neoadjuvant chemotherapy (NAC) but metastasis/ses in the nodes from the axillary lymph node dissection performed after NAC will be analysed. In substudy II we also investigate the false negative rate in sentinel lymph node biopsies performed after NAC if the patient had positive lymph nodes at diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The number of successful sentinel lymph node biopsies among the total number of attempted biopsies. Will be analyses both before and after neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <enrollment type="Actual">224</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically verified breast cancer planned for neoadjuvant chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically node-negative (or unclear nodal status) substudy I

          -  signed consent from the study participant

        Exclusion Criteria:

          -  inflammatory breast cancer

          -  cytologically verified lymph node metastasis/es at diagnosis (substudy I), but these
             patients can be included in substudy II

          -  patients not able to give an informed consent

          -  hypersensitivity or allergy against blue dye or isotope
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda H Zetterlund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Research and Education, Karolinska Institutet, Stockholm South General Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fuat Celebioglu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medical Research and Education, Karolinska Institutet, Stockholm South General Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Frisell, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Falu lasarett</name>
      <address>
        <city>Falun</city>
        <zip>791 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Sahlgrenska</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset i Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborgs lasarett</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsjukhuset i Karlstad</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blekingesjukhuset Karlskrona</name>
      <address>
        <city>Karskrona</city>
        <zip>371 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsjukhuset i Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus, Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus, Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio St Görans Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset/Stockholm South General Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset i Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset Sundsvall-Härnösand</name>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NU-sjukvården, Uddevalla sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset i Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet i Västerås</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasaretttet i Växjö</name>
      <address>
        <city>Växjö</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul;230(1):72-8.</citation>
    <PMID>10400039</PMID>
  </reference>
  <reference>
    <citation>Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14.</citation>
    <PMID>14559892</PMID>
  </reference>
  <reference>
    <citation>Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005 Apr 20;23(12):2694-702. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808. Sovan, Atilla [corrected to Soran, Atilla].</citation>
    <PMID>15837984</PMID>
  </reference>
  <reference>
    <citation>Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006 May;93(5):539-46.</citation>
    <PMID>16329089</PMID>
  </reference>
  <reference>
    <citation>Schrenk P, Hochreiner G, Fridrik M, Wayand W. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003 Jul-Aug;9(4):282-7.</citation>
    <PMID>12846861</PMID>
  </reference>
  <reference>
    <citation>Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, Sadetzki S. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2008 Nov 1;98(6):403-6. doi: 10.1002/jso.21128.</citation>
    <PMID>18683193</PMID>
  </reference>
  <reference>
    <citation>Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.</citation>
    <PMID>23683750</PMID>
  </reference>
  <reference>
    <citation>Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.</citation>
    <PMID>24101169</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stockholm South General Hospital</investigator_affiliation>
    <investigator_full_name>Linda Zetterlund</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>sentinel lymph node biopsy</keyword>
  <keyword>false negative rate</keyword>
  <keyword>identification rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

